Abstract: Examples of the present disclosure describe systems and methods for enterprise search that leverage periodically updated user context of an enterprise user for intent understanding and treat a search session as a dialog between the user and a digital assistant to allow multi-modal interaction. For example, a query input by the user may be received from a client application having search functionality and an integrated assistant. A current state of the user context may be leveraged to understand the query. Based on the understanding, one or more responsive entities may be retrieved from an enterprise search index as results. Based on the results, a response may be generated that includes the results and a prompt to cause the user to further refine the query and/or provide feedback. The response may be provided to the client application for output as part of a search session dialog between the user and assistant.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: A display substrate and a preparation method thereof, and a display apparatus. The display substrate includes a base substrate, at least one insulating film layer disposed on the base substrate, and a first electrode disposed on a side of the at least one insulating film layer away from the base substrate; wherein a concave-convex structure is disposed on a side of the at least one insulating film layer away from the base substrate, and there is an overlapping area between an orthographic projection of the concave-convex structure on the base substrate and an orthographic projection of the first electrode on the base substrate.

Abstract: Examples of the present disclosure describe systems and methods for enterprise search that leverage periodically updated user context of an enterprise user for intent understanding and treat a search session as a dialog between the user and a digital assistant to allow multi-modal interaction. For example, a query input by the user may be received from a client application having search functionality and an integrated assistant. A current state of the user context may be leveraged to understand the query. Based on the understanding, one or more responsive entities may be retrieved from an enterprise search index as results. Based on the results, a response may be generated that includes the results and a prompt to cause the user to further refine the query and/or provide feedback. The response may be provided to the client application for output as part of a search session dialog between the user and assistant.

Abstract: Examples of the present disclosure describe systems and methods for generating multiple semantic hypotheses for search query intent understanding. In aspects, a search query may be received by a query analysis component associated with a search system. The query analysis component may be used to evaluate the search query for ambiguity in the domain, intent, and/or slot(s) of the search query. A set of hypotheses representing for one or more combinations of the domain, intent, and/or slot(s) of the search query may be generated. The set of hypotheses may be scored and/or ranked. Based on the scores/ranks, one or more of the hypotheses in the set of hypotheses may be provided to a user and/or one or more processing components accessible to the search system.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present disclosure proposes a modeling method and apparatus for diagnosing an ophthalmic disease based on artificial intelligence, and a storage medium. The modeling method includes: establishing a data collection of ophthalmic images and a data collection of non-image ophthalmic disease diagnosis questionnaires; training a first neural network model by employing the data collection of the ophthalmic images to obtain a first classification model; training a second classification model by employing the data collection of non-image ophthalmic disease diagnosis questionnaires; and merging the first classification model and the second classification model to obtain a target classification network model, in which, a test result outputted by the target classification network model is used as a diagnosis result of the ophthalmic disease.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: Examples of the present disclosure describe systems and methods for enterprise search that leverage periodically updated user context of an enterprise user for intent understanding and treat a search session as a dialog between the user and a digital assistant to allow multi-modal interaction. For example, a query input by the user may be received from a client application having search functionality and an integrated assistant. A current state of the user context may be leveraged to understand the query. Based on the understanding, one or more responsive entities may be retrieved from an enterprise search index as results. Based on the results, a response may be generated that includes the results and a prompt to cause the user to further refine the query and/or provide feedback. The response may be provided to the client application for output as part of a search session dialog between the user and assistant.

Abstract: Examples of the present disclosure describe systems and methods for generating multiple semantic hypotheses for search query intent understanding. In aspects, a search query may be received by a query analysis component associated with a search system. The query analysis component may be used to evaluate the search query for ambiguity in the domain, intent, and/or slot(s) of the search query. A set of hypotheses representing for one or more combinations of the domain, intent, and/or slot(s) of the search query may be generated. The set of hypotheses may be scored and/or ranked. Based on the scores/ranks, one or more of the hypotheses in the set of hypotheses may be provided to a user and/or one or more processing components accessible to the search system.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: A method, an apparatus and a system for information retrieval are provided. The method for information retrieval may comprise: receiving a query in a natural language form from a user (210); extracting a plurality of feature vectors from the query based on a plurality of knowledge entries in a knowledge base associated with the user and a built-in featurization source, one feature vector per knowledge entry (220); obtaining, with a pre-trained language understanding model, a plurality of language understanding results based on the plurality of feature vectors (230); and selecting a knowledge entry corresponding to the query among the plurality of entries based on the plurality of language understanding results (240). The method may extract more features and combine information retrieval and language understanding in one shot to improve efficiency.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: The present disclosure proposes a modeling method and apparatus for diagnosing an ophthalmic disease based on artificial intelligence, and a storage medium. The modeling method includes: establishing a data collection of ophthalmic images and a data collection of non-image ophthalmic disease diagnosis questionnaires; training a first neural network model by employing the data collection of the ophthalmic images to obtain a first classification model; training a second classification model by employing the data collection of non-image ophthalmic disease diagnosis questionnaires; and merging the first classification model and the second classification model to obtain a target classification network model, in which, a test result outputted by the target classification network model is used as a diagnosis result of the ophthalmic disease.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.